Roche (RHHBY) said it shared real-world evidence from the rollout of Accu-Chek SmartGuide continuous glucose monitoring solution at the European Association for the Study of Diabetes annual meeting on Tuesday, and announced its integration with the mySugr diabetes management app. “The Accu-Chek SmartGuide CGM solution is a significant step towards providing greater peace of mind for people living with diabetes, due to the AI-enabled predictive capabilities it offers. This empowers patients to take action before undesired events occur,” said Rodrigo Diaz de Vivar, Lifecycle Leader Patient Insights, Roche Diagnostics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Trump Weekly: Trump signs pharma order, FTC opens inquiry into AI chatbots
- Advertising, drugmaker stocks in spotlight as Trump moves to regulate pharma ads
- Omnicom, WPP under pressure after Trump moves to regulate pharma ads
- Trump Trade: U.S. President signs new pharma order
- Trump signs memorandum mandating pharma ads give more info on risks